Smoking is directly responsible for approximately 90% of lung cancers and is also strongly associated with cancers of the head and neck, esophagus and urinary bladder. Our growing understanding of the molecular changes that underlie cancer progression has contributed to the development of novel molecular approaches for the detection of cancer. In this study, we review a number of recent studies that have used molecular techniques to detect neoplastic DNA from lung, head and neck, esophagus and bladder cancer. The majority of these approaches are based on polymerase chain reaction (PCR) based assays. These PCR-based techniques can detect a few clonal cancer cells containing a specific DNA mutation, microsatellite alteration, or CpG island methylation among an excess background of normal cells. The ability to accurately detect a small number of malignant cells in a wide range of clinical specimens including sputum, saliva, bronchoalveolar lavage fluid, urine, serum, plasma, or tissue has significant implications for screening high-risk individuals (such as cigarette smokers) for cancer.
Introduction
Tobacco smoking is the major cause of lung cancer and is strongly associated with cancer of the head and neck, esophagus and urinary bladder (Doll, 1998) . Smoking accounts for at least 30% of cancer deaths and is the single leading cause of cancer death in the United States (Carbone, 1992) . Over the past decade, advances in molecular biology have revolutionized our understanding of cancer initiation and progression. It is generally accepted that cancer arises as a result of the accumulation of a series of genetic alterations in oncogenes and tumor suppressor genes. A number of DNA alterations (gene mutation, microsatellite instability, promoter methylation, and overexpression) occur during the development of cancer and can be used as markers for cancer detection in clinical samples (Sidransky, 1995 (Sidransky, , 1997 Ahrendt and Sidran-sky, 1999) . In addition, the detection of molecular changes present in invasive cancer may identify high-risk populations and ultimately may define molecular criteria for the diagnosis of cancer (Sidransky, 1997; Ahrendt and Sidransky, 1999) . Over the past decade, a variety of approaches have been developed to potentially improve the results of conventional cancer screening by detecting these molecular markers in clinical samples. This review will focus on nucleic acid-based detection approaches for smoking-associated tumors.
Lung cancer
Lung cancer is the leading cause of death among smokers, and the most common cause of cancerrelated death among both males and females in the USA and other developed countries. In 2001, an estimated 169 500 new cases of primary lung cancer were diagnosed and an estimated 157 400 people died of this disease in the USA (Greenlee et al., 2001) . Epidemiological studies have demonstrated that most cases of lung cancer are directly attributable to cigarette smoking (Carbone, 1992; Shopland et al., 1991) . Only 5 -10% of all of the lung cancers occur in patients without a prior history of cigarette smoking (Ahrendt et al., 2000; Shopland et al., 1991) . Compared with non-smokers, smokers have a 10-fold greater risk of dying from lung cancer and in heavy smokers this risk increases to 15 -25-fold (Carbone, 1992) . Surgical resection remains the most effective form of treatment for non-small cell lung cancer (NSCLC); however, at the time of diagnosis more than 65% of all patients will have advanced disease that is no longer amenable to curative therapy (Naruke et al., 1988) . Earlier diagnosis of patients with lung cancer would increase the number of potentially resectable patients, but better detection approaches are needed. Several large prospective randomized trials have demonstrated that conventional sputum cytology is no more effective than annual chest radiographs in detecting lung cancer (Berlin et al., 1984) . Although periodic screening with chest radiographs has also not been demonstrated to decrease lung cancer mortality, their efficacy in lung cancer screening remains controversial (Strauss et al., 1997) .
Detection of molecular alterations in sputum or bronchoalveolar lavage fluid
The majority of molecular screening studies for lung cancer performed to date have focused on detecting genetic abnormalities in exfoliated cells from body fluid samples, including sputum or bronchoalveolar lavage (BAL) fluid, or in the circulating DNA found in serum or plasma (Table 1) . K-ras gene mutations were one of the earliest molecular abnormalities detected in lung cancer and was among the first targets in molecular screening studies. The K-ras gene is mutated in 40 -50% of primary adenocarcinomas of the lung and the vast majority of mutations are confined to codon 12 simplifying the strategy for detecting mutations. Mills et al. (1995) used a mutant enriched PCR technique to detect K-ras mutations in BAL fluid obtained from patients with NSCLC. This technique uses PCR primers which create a BstN1 restriction site at codon 12 in tumors with wild-type K-ras. After BstN1 digestion, mutant K-ras alleles are selectively amplified.
With this approach, mutant K-ras alleles were detected in the BAL fluid from 56% of patients with primary adenocarcinoma of the lung and in 31% of all patients with NSCLC (Mills et al., 1995) . K-ras mutations were not detected in the thirty control patients. Tumor tissue was available in 35 of 56 patients with NSCLC, and in all cases the K-ras mutation status of the BAL fluid was identical to the primary tumor. The sensitivity for diagnosing adenocarcinoma in this group of patients with unspecified stage lung cancer was high and the specificity was 100% (Table 1) (Mills et al., 1995) .
A similar study using mutant enriched PCR also reported K-ras mutations in 60% of NSCLC tumors and 47% of sputum samples from patients with NSCLC (Yakubovskaya et al., 1995) . However, K-ras mutations were also detected in normal appearing lung tissues from 60% of patients with NSCLC, 10% of lung tissue samples from patients without cancer, and in 12.5% of sputum samples from patients with benign lesions, suggesting a less than perfect specificity of this technique for overt cancer. Mutant-enriched PCR is able to detect K-ras mutant cells with a sensitivity of 1 in 10 4 to 10 6 normal cells. However, as the number of PCR cycles and sensitivity of this assay increased, the specificity was compromised, limiting its value as a screening test (Ahrendt et al., 1999a; Mills et al., 1995; Yakubovskaya et al., 1995) . Furthermore, K-ras mutations are only detected in a minority of adenocarcinomas of the lung (30 -50% of cases), limiting their use as a marker for lung cancer (Ahrendt et al., 2001) .
K-ras mutations have also been detected in the sputum of patients with adenocarcinoma of the lung, using a semiquantitative plaque hybridization assay. Mao et al. (1994) were the first to report tumor-specific K-ras mutant cells in seven of eight cytologically negative archived sputum samples obtained from patients before they were diagnosed with lung cancer . In addition, p53 mutant cells were also detected in one out of two patients with a tumor containing a p53 mutation. The sputum sample containing p53 mutant cells was obtained 13 months prior to the patient's diagnosis of lung cancer. The plaque hybridization assay is cumbersome but able to detect one mutant cell against a background of 10 000 normal cells, and is limited only by the number of plaques screened .
Microsatellite alterations represent another molecular screening tool for the detection of cancer. initially screened 100 primary cancers, including 58 lung cancers (35 small cell lung cancer (SCLC), 23 NSCLC) with a panel of nine tri-and tetranucleotide markers, and identified microsatellite instability in 26 of the tumors, including 50% of the SCLCs and 9% of the NSCLCs, respectively . In serial dilution experiments, the presence of these novel alleles (or bands) could be detected with a sensitivity of 1 in 200 to 1 in 500 . They also examined sputum samples collected from two patients with SCLC with markers demonstrating instability in the primary tumor. Both of these sputum samples contained the same new allele found in the tumor .
To further examine the sensitivity of many of these molecular screening strategies in detecting cancer in patients with potentially curable lung cancer, Ahrendt et al. (1999a) evaluated four PCR-based assays based on the detection of four common molecular markers (frequently abnormal in NSCLC) in the BAL fluid from 50 patients with resectable (stage I to IIIa) NSCLC (Table 2) . Since most molecular markers are only present in a minority of patients with a particular malignancy, screening for multiple markers increases the likelihood that at least one particular genetic alteration will be present in the primary tumor, thereby increasing the potential of detecting these alterations in cytological fluid samples from a given patient. Twentyeight of these 50 tumors contained a p53 mutation and the identical mutation was detected with a plaque hybridization assay in the BAL fluid in 39% of these patients. Eight of 19 primary adenocarcinomas contained a K-ras mutation, and the identical mutation was detected with a mutation ligation assay in the BAL fluid in 50% of these patients. The p16 gene harbored promoter hypermethylation in 19 of 50 tumors, and methylated p16 alleles were detected in the BAL fluid from 63% of these patients using methylation-specific PCR. Microsatellite instability in at least one marker was detected, with a panel of 15 markers frequently altered in NSCLC in 23 of 50 tumors. However, the identical alteration was detected in the BAL fluid in only 14% of these patients. When all four techniques were combined, at least one genetic alteration was present in the tumor in 43 patients (86%) and each of these alterations was used to screen the BAL fluid. A mutation, methylation, or microsatellite instability was detected in the paired BAL fluid of 23 of these 43 patients (53%) with resectable NSCLC (Ahrendt et al., 1999a) .
Several factors influenced the ability to detect molecular alterations in BAL fluid in this study (Ahrendt et al., 1999a) . Tumor-specific p53 mutations were detected significantly more often in BAL fluid from patients with centrally located tumors than in BAL fluid from patients with tumors located in the parenchyma or peripherally (100% versus 29%). Tumor size also played a significant role in the ability to detect molecular alterations in the BAL fluid. Only one of 11 stage IA (43.0 cm) tumors had a detectable p53 mutation in the BAL fluid and this tumor was 3.0 cm in size. The p53 plaque hybridization assay detected molecular alterations in the BAL fluid from patients with advanced (stages IB, II and IIIa) tumors more often than in limited stage IA (43.0 cm) tumors (59% versus 9%). In contrast to cytology, which is much more sensitive at detecting squamous cell cancer than adenocarcinoma, the molecular assays detected cancer cells in the BAL fluid from these two tumor types with similar frequency (Ahrendt et al., 1999a) .
More recently, Palmisano et al. (2000) developed a nested methylation-specific PCR method, which has a 50-fold greater sensitivity than the original methylation-specific PCR (detection limit=one methylated allele in 450 000 unmethylated alleles). Using this assay, aberrant p16 methylation was detected in the sputum samples from all eight patients (100%) with p16 methylation in the primary squamous cell lung cancer. In addition, aberrant methylation of the O 6 -methylguanine DNA methyltransferase gene (MGMT) was detected in the sputum samples in four of the six patients (67%) with corresponding MGMT methylation in the primary tumor. Aberrant p16 and/or MGMT methylation was present in 100% of tumors and corresponding sputum samples in patients with squamous cell lung cancer. In contrast, sputum cytology detected cancer cells in only 40% of these samples (Palmisano et al., 2000) . The authors further demonstrated that aberrant p16 or MGMT methylation in sputum samples could be detected from 5 to 35 months before clinical detection of squamous cell cancer in another 11 patients with lung cancer. The methylation status of the sputum sample matched the methylation status of the corresponding tumor in 90% of cases with the p16 assay, and in 78% of cases with the MGMT assay (Palmisano et al., 2000) . Aberrant methylation in the p16 and MGMT genes was also detected in 14% of cancer-free and 23% long-term tobacco smokers. This sensitive assay may detect individuals at high-risk of developing squamous cell lung cancer, although follow-up is limited. The detection of aberrant hypermethylation of cancer related genes in the sputum shows promise as a new approach for detecting lung cancer, but long-term follow-up is essential to fully define the significance of false positives with these very sensitive techniques.
Mitochondrial DNA mutations were identified in human cancer and subsequently used as a tool for molecular cancer detection. Fliss et al. (2000) identified mitochondrial DNA mutations in 43% (6 of 14) of NSCLCs. Using a sensitive oligonucleotide-mismatch ligation assay, mitochondrial DNA mutations were present in 80% (8 of 10) of corresponding BAL samples from lung cancer patients (Fliss et al., 2000) . Mitochondrial DNA analysis has one distinct advantage over other nuclear DNA-based methods for cancer detection (Fliss et al., 2000) . Each cell contains 100 to 1000's of mitochondrial genomes, and cancer cells have an increased number of mitochondria in their cytoplasm. Moreover, mutated mitochondrial DNA appears to gain a significant replicative advantage over wild-type mitochondrial DNA, eventually becoming homoplasmic (when all mitochondria share the same genome). The end result is considerable amplification (20 -200-fold) of tumor-derived mutated mitochondrial DNA (Figure 1) (Fliss et al., 2000) . Moreover, a mononucleotide repeat (D310) has recently been identified as a frequent mutational hotspot for mitochondrial DNA alterations in a variety of primary tumors, including lung cancer (SanchezCespedes et al., 2001) . The identification of mitochondrial DNA mutation hot-spot D310 could simplify the strategy for detecting mitochondrial DNA mutation in clinical samples. In addition, gene chip/array technologies can be applied to develop high throughput analysis of the entire mitochondrial genome as previously demonstrated for nuclear p53 mutations (Ahrendt et al., 1999b) .
Detection of molecular alterations in circulating DNA
Molecular approaches have also been applied to detect tumor-specific alterations in circulating DNA. The concentration of DNA in the serum of patients with cancer is significantly higher than cancer-free individuals and provides another potential source for non-invasive molecular detection of cancer. Chen et al. (1996) identified microsatellite instability in 76% (16 of 21) of SCLC tumors, and further demonstrated that 93% (15 of 16) of the patients with microsatellite instability in tumor DNA also had similar microsatellite alterations in the corresponding plasma DNA. Follow-up examinations of plasma DNA after 3 -6 months revealed identical microsatellite alterations in three out of four patients, suggesting the circulating DNA came from the tumor (Chen et al., 1996) . Methylation specific PCR has also been used to identify tumor-specific epigenetic alterations in the serum of patients with lung cancer. Esteller et al. (1999) initially screened 22 primary NSCLCs with four candidate methylation genes, and detected aberrant methylation in 68% (15 of 22) of the primary NSCLCs in at least one of these four genes: 41% (9 of 22) for p16, 23% (5 of 22) for the metastasis suppressor gene DAP-K, 9% (2 of 22) for the detoxification gene GSTP1, and 27% (6 of 22) for the DNA repair gene MGMT. In contrast, none of the 22 corresponding normal lung tissues demonstrated aberrant methylation in any of these four genes (Esteller et al., 1999) . More importantly, identical aberrant methylation was detected in the corresponding serum in 11 of these 15 patients (73%) with aberrant methylation in the primary tumors. Specifically, aberrant methylation in serum was detected in 33% of samples (3 of 9) for p16, 80% of samples (4 of 5) for DAP-K, 50% of samples (1 of 2) for GSTP1, and 66% of samples (4 of 6) for MGMT. In contrast, none of the patients with unmethylated tumor DNA showed methylation in their corresponding serum (Esteller et al., 1999) . Recently, aberrant adenomatous polyposis coli (APC) promoter hypermethylation has been detected in 95 of 99 (96%) of lung cancer tissues and provides an additional target for a serum-based screening test for lung cancer (Usadel et al., 2002) . Aberrant APC gene methylation was detected in the serum or plasma in 42 of 89 (47%) patients with lung cancer, but was undetected in 50 healthy control patients (Usadel et al., 2002) . Promoter hypermethylation is an important pathway for silencing gene transcription in cancer cells. As the list of methylated genes in cancer increases in conjunction with improved high throughput techniques, detection of gene methylation in clinical samples such as sputum, BAL fluid, and serum will be more fully explored in larger clinical trials.
Head and Neck Squamous Cell Cancer (HNSCC)
Head and neck cancer includes cancers arising from the oral cavity, pharynx, and larynx. The majority of head and neck cancers are squamous cell carcinomas. Tobacco smoking and alcohol consumption are the major risk factors for head and neck cancers, accounting for approximately three-fourths of these cancers in the USA (Blot et al., 1988) . Every year, there are approximately 500 000 new cases of head and neck squamous cell carcinoma worldwide, and over 50 000 cases in the USA (Vokes et al., 1993) . In addition, molecular studies have demonstrated that head and neck squamous cell carcinomas have a similar p53 gene mutation pattern found in squamous cell carcinoma of the lung, further implicating tobacco-derived carcinogens at the molecular level in the etiology of head and neck squamous cell carcinoma (Boyle et al., 1993) .
A variety of genetic changes have frequently been found in head and neck cancers, including a high frequency of allelic loss on chromosomes 9p (72%), 3p (67%), 11q (61%), 13q (54%), and 17p (52%) (Nawroz et al., 1994) . p53 gene mutations are also present in approximately one-half of head and neck cancers (Boyle et al., 1993) . Using plaque hybridization, Boyle et al. (1994) identified tumor-specific p53 mutations in five out of seven (71%) saliva samples from patients with head and neck cancer. This study also demonstrated that for every 100 cells in the saliva, two or three cells had exfoliated from the patient's cancer and contained the same p53 mutation (Boyle et al., 1994) . Promoter hypermethylation of several genes has been reported in head and neck cancer and provides another potential target for detecting exfoliated cancer cells. Rosas et al. (2001) identified aberrant methylation of at least one of three genes (p16, MGMT, or DAP-K) in 17 of 30 (56%) head and neck primary tumors; 14 (47%) of 30 at p16, 10 (33%) of 30 at DAP-K, and 7 (23%) of 30 at MGMT. Abnormal promoter hypermethylation was also detected in the matched saliva sample in 11 of these 17 (65%) patients (Rosas et al., 2001) . The identification of cancer cells in the saliva using molecular approaches has potential applications in screening smokers for head and neck cancer.
Mitochondrial DNA mutations have also been useful targets to detect exfoliated HNSCC cells in saliva. Mitochondrial DNA mutations have been identified in 46% of head and neck cancers (Fliss et al., 2000) . Importantly, the same mitochondrial DNA mutations were detected in 67% (6 of 9) of saliva samples from head and neck cancer patients by direct sequencing alone (Fliss et al., 2000) . A greater sensitivity should be feasible through the use of more sensitive assays to detect these mutations. As further mitochondrial DNA mutations are profiled in larger numbers of primary head and neck cancers, a mitochondrial DNA mutation chip/array could be developed to detect these mutations as discussed above (Ahrendt et al., 1999b) .
Surgical resection and radiotherapy are the principal therapies for the majority of localized head and neck cancers. The most important factor determining the risk of local failure following resection is complete surgical removal of the tumor (Brennan et al., 1995) . Current pathological analysis may fail to detect small numbers of cancer cells at the margins of resection (Fielding et al., 1992) . Local recurrence occurs in up to 50% of patients with microscopically negative surgical margins, and in these patients it is the leading cause of treatment failure (Davidson et al., 1981) . Local recurrence is a significant clinical problem in head and neck cancer and p53 mutations have demonstrated potential in monitoring for recurrence following resection of head and neck cancer (Boyle et al., 1993; Brennan et al., 1995) . Brennan et al. (1995) evaluated the surgical margins of these patients for p53 mutant cells to identify patients at high risk of recurrence at the resection. The p53 gene was initially sequenced in 69 primary invasive head and neck squamous cell carcinomas and mutations were identified in 30 (43%) patients. Using a PCR-based p53 mutant-specific oligonucleotide plaque hybridization approach, which can detect one mutant cancer cell among 10 000 normal cells, 72 surgical margins from the 25 patients with histologically negative margins were analysed for p53 mutant cells. Molecular analysis detected tumor-specific p53 mutations in at least one resection margin from 13 of these 25 patients (52%), demonstrating that these apparently microscopic negative surgical margins harbored occult cancer cells. The percentage of residual neoplastic cells in the surgical margins ranged from 0.05 to 28.0% (Brennan et al., 1995) . The high incidence (52%) of residual cancer cells in these surgical margins detected by this molecular assay closely approximated the percentage (50%) of patients who have local recurrences after surgical removal of head and neck cancer (Davidson et al., 1981) . Furthermore, five of the 13 patients (38%) with p53 mutation positive margins had local recurrences after a median follow-up of 17 months, whereas none of the 12 patients with p53 mutation negative margins recurred locally (Brennan et al., 1995) . Patients with molecular positive margins had a substantially increased risk of local recurrence, suggesting that initial margin analysis and postoperative follow-up using molecular techniques may aid in the treatment of patients with HNSCC (Brennan et al., 1995) . One-half of head and neck cancers harbor a p53 mutation, but this approach could be augmented by adding additional molecular targets (Boyle et al., 1993) .
For example, PCR-based microsatellite analysis has also been used in predicting recurrence or in HNSCC detection. Sardi et al. (2000) examined 61 histopathologically negative surgical margins from 25 patients with head and neck cancer. Sixteen margins from 11 (44%) patients showed microsatellite alterations identical to the primary cancers. The cancer recurred locally in seven of these 11 (64%) patients with microsatellite positive margins, whereas only one of the 14 patients with microsatellite negative margins had local recurrence (Sardi et al., 2000) . Cox regression analysis showed that microsatellite positive margins were an independent prognostic factor (P=0.04) for local recurrence.
Analysis of serum or plasma for molecular abnormalities common in HNSCC may also be a useful diagnostic approach for this disease. Using 12 microsatellite markers, Nawroz et al. (1996) identified tumor-specific microsatellite alterations in the serum in 29% (6 of 21) of patients with head and neck cancer. All six patients with detectable microsatellite alterations in serum had advanced stage HNSCC and five of these patients had nodal metastases, three developed distant metastases, and four died of disease (Nawroz et al., 1996) . Although the sensitivity may not be high enough to detect HNSCC at an early stage, this study indicated that microsatellite alterations in serum DNA could be detectable in patients with advanced head and neck cancer and might be useful in predicting poor prognosis.
Methylation-specific PCR has also been used as a serum-based detection tool in HNSCC. In a large study, Sanchez-Cespedes et al. (2000) screened 95 head and neck cancers for promoter hypermethylation, and detected hypermethylation in 55% (52 of 95) of the patients in at least one of three genes: p16 (27%), MGMT (33%), and DAP-K (18%). Among the 50 patients with paired serum for analysis, 42% (21 of 50) of cases had the identical methylation pattern in the corresponding serum including 31% (8 of 26) in p16, 48% (14 of 29) in MGMT, and 18% (3 of 17) in DAP-K hypermethylation. Five of the 21 patients with hypermethylated serum DNA developed metastasis, whereas only one of the 29 patients without hypermethylated serum DNA developed metastasis (Sanchez-Cespedes et al., 2000) .
Molecular approaches may also be used to identify the occult primary tumor when a patent presents only with a metastatic cervical lymph node. Using microsatellite analysis, Califano et al. (1999) examined the cervical metastatic tumors from 18 patients with unknown primary head and neck cancer and corresponding biopsies of the oral cavity and pharynx. These investigators found that in 10 of the 18 patients (55%), the identical molecular alterations identified in the metastatic cervical lymph node tumors were present in at least one random mucosal biopsy specimen from defined biopsy sites (i.e., most likely anatomic sites to harbor an occult primary tumor) (Califano et al., 1999) . In three patients, the primary tumor subsequently appeared 1 to 13 years later in the predicted site identified by the molecular assay. All three primary tumors had the same molecular changes as those in the benign mucosal biopsies and in the metastatic cervical lymph nodes (Califano et al., 1999) .
Esophageal cancer
Esophageal cancer is the ninth most common malignancy and ranks as the sixth most frequent cause of cancer related death throughout the world (Blot, 1994 ). There are two major histological types of this cancer: squamous cell carcinoma and adenocarcinoma. The former is related to smoking and alcohol consumption, whereas the latter is associated with Barrett's esophagus, a premalignant lesion characterized by columnar epithelial metaplasia predominantly caused by chronic gastroesophageal reflux (Barrett et al., 1999) . Worldwide, approximately 300 000 new cases of esophageal cancer are diagnosed every year (Parkin et al., 1993) . The incidence of esophageal cancer has been rising dramatically in the USA and western Europe over the past two decades (Devesa et al., 1998) . Epidemiologic studies have demonstrated that tobacco smoking and alcohol consumption are the major risk factors for esophageal cancer in North America (Hu et al., 2000) . It is estimated that 90% of esophageal cancer is related to tobacco smoking and alcohol consumption in North America and Europe (Parkin et al., 1999) .
A variety of molecular approaches have been used to augment traditional methods (endoscopy) used to detect esophageal cancer. Methylation of the p16 gene is common in esophageal squamous carcinoma. Hibi et al. (2001) initially screened 38 esophageal squamous cell carcinomas for p16 promoter methylation and detected p16 methylation in 82% (31 of 38) of esophageal cancers. Among the 31 patients with p16 methylation in the primary esophageal cancer, 23% (7 of 31) of patients also had detectable p16 promoter methylation in the corresponding serum DNA. No methylation was detected in the serum of seven esophageal cancer patient without p16 methylation in the primary tumor (Hibi et al., 2001) . Similarly, APC gene promoter hypermethylation has been detected in 92% (48 of 52) of esophageal adenocarcinomas, 40% (17 of 43) of Barrett's metaplastic lesions, and 50% (16 of 32) esophageal squamous cell cancers (Kawakimi et al., 2000) . APC gene promoter hypermethylation was also detected in 13 of 52 (25%) plasma samples from patients with esophageal adenocarcinoma, and elevated plasma levels of hypermethylated APC DNA were associated with a significant decrease in survival (Kawakimi et al., 2000) . These studies indicate that the same tumorspecific DNA alterations can be detected in the serum of patients with esophageal cancer, although the sensitivity was limited. As more new methylated target genes (such as MGMT, DAP-K, E-Cadherin and GSTP1) are identified in esophageal cancer, the use of multiple target genes might improve this and similar approaches.
Bladder cancer
Bladder cancer is the fourth most common malignancy in men and the eighth most common malignancy in women in the USA (Landis et al., 1998) . It is the second most common genitourinary malignancy, accounting for more than 54 000 new cases and 12 400 deaths in 2001 (Greenlee et al., 2001) . Worldwide, approximately 261 000 new cases of bladder cancer are diagnosed each year (Parkin et al., 1999) . Tobacco smoking is a major risk factor for bladder cancer and responsible for about 45% of bladder cancers (Parkin et al., 1999; Hemstreet et al., 2001) . Compared with non-smokers, smokers have 2 -4-fold higher risk of developing bladder cancer (Hartge et al., 1987; Burch et al., 1989; Clavel et al., 1989; Morrison et al., 1984; Taylor et al., 1998) . Although 70% of patients present with superficial bladder cancers, many patients often have recurrences and require close surveillance (Steiner et al., 1997) . Urine cytology is a common non-invasive procedure for the diagnosis of bladder cancer, but it can miss up to 50% of tumors (Murphy et al., 1984) . Cystoscopy, which allows direct visualization and biopsy of suspicious bladder lesions, is currently the 'gold standard' for diagnosis. However, it is invasive, expensive and uncomfortable for the patient.
In 1990, p53 gene mutations were identified in the urine sediments of three patients with bladder cancer (Sidransky et al., 1991) . In each of the three patients, the same mutation detected in the primary bladder cancer was identified in the corresponding urine sediment through mutant-specific oligonucleotide hybridization and direct sequencing. This pioneering study demonstrated the first example of the successful use of molecular approaches at detecting cancer cells from solid tumors in clinical specimens (Sidransky et al., 1991) .
Mutations in other tumor suppressor genes and oncogenes have been used to identify bladder cancer cells in the urine. Using single-strand conformation polymorphism (SSCP) analysis and sequencing, Fitzgerald et al. (1995) detected H-ras gene mutations in urine samples from 44% (44 of 100) of the patients with bladder cancer, whereas urine cytology was positive in 33% (31 of 93) of the patients. More importantly, SSCP analysis detected H-ras mutations in 47% of the patients with low grade bladder cancer. In contrast, urine cytology detected cancer cells in only 16% of patients with low grade bladder cancer. Combined results from H-ras mutation analysis and cytology substantially increased the sensitivity of tumor detection up to 60% (Fitzgerald et al., 1995) . However, this study must be interpreted with caution because Hras mutations are not frequently identified by others in bladder cancer.
More recently, PCR-based microsatellite analysis of the urine DNA has proved quite successful at detecting both primary and recurrent bladder cancer (Mao et al., 1996; Steiner et al., 1997) . In a blinded study, using 13 pre-selected microsatellite markers, Mao et al. analysed the urine samples from 25 patients with suspicious bladder lesions on cystoscopy, and compared the microsatellite analysis with the cytological results. Microsatellite changes matching those in the tumor were detected in the urine sediments of 95% of the patients with bladder cancer, whereas urine cytology detected cancer cells in only 50% of these samples (Mao et al., 1996) . Similar approaches have been applied to test serial urine sediments from 21 patients after the initial treatment of bladder cancer (Steiner et al., 1997) . Microsatellite analysis detected tumor-specific microsatellite alterations in 10 out of 11 patients with recurrence, and correctly predicted the existence of a neoplastic cell population in the urine of two patients, 4 and 6 months before cystoscopic evidence of the cancer. This assay was negative in all 10 patients without evidence of cancer (Steiner et al., 1997) . Subsequent studies from other investigators have confirmed the reliability of the PCR-based microsatellite analysis of the urine sediments, with 83% sensitivity and 100% specificity (Mourah et al., 1998) . These studies support further study of microsatellite analysis of urine sediment DNA for the detection of primary and recurrent bladder cancer.
Recently, the CD44 variant CD44v8-10 has been found to be a promising molecular marker for detecting bladder cancer from urine sediments, since this molecule is overexpressed in bladder cancer but not in benign bladder lesion . Using competitive reverse transcription -PCR (RT -PCR), Okamoto et al. (1998) identified CD44v8-10 mRNA overexpression in 75% (15 of 20) of the urine samples from 20 patients with bladder cancer, whereas urine cytology detected cancer cells in only 47% of these samples. This assay was negative in all 20 urine samples with benign lesions. A similar technique was reported in a larger series study from this same group . Miyake et al. (1998) initially screened the expression of CD44 variant with RT -PCR in 30 urothelial cancers and corresponding normal urinary tissues and found that CD44v8-10 mRNA was overexpressed in 77% (23 of 30) of urothelial cancers, whereas any CD44 variants including CD44v8-10 were undetectable in normal urinary tissues. In addition, CD44v8-10 mRNA overexpression in urine samples was detected in 77% (62 of 80) of patients with urothelial cancer, whereas this assay was negative in all patients with benign lesions. Furthermore, the sensitivity of CD44v8-10 overexpression was not affected by tumor grade, whereas the sensitivity of cytology declined in more well differentiated tumors .
Another promising predictive molecular marker is survivin, an inhibitor of apoptosis which can be detected in 78% of bladder cancers but is undetectable in normal urothelium (Swana et al., 1999) . With RT -PCR, survivin expression was detected in 100% (15 of 15) of urine samples from patients with bladder cancer but was not detected in the normal control urine samples (Smith et al., 2001) . Lastly, the detection of mitochondrial DNA mutations in urine was also used for the detection of bladder cancer. Mitochondrial DNA mutations were present in 64% of primary bladder cancers and mitochondrial DNA mutations identical to that in the primary bladder tumors were easily detected by sequencing in three matched urine samples from bladder cancer patients (Fliss et al., 2000) .
Summary
Promising results have been reported using several molecular detection strategies for the detection of common smoking-related cancers. These early studies have clearly demonstrated the potential improvement in sensitivity and specificity of molecular approaches in detecting cancer. However, before the introduction of these approaches into routine clinical use, further larger clinical studies are clearly needed. A prospective comparison between conventional cancer detection methods and newer molecular techniques, documenting improved detection rates in patients with early stage cancers is required before these approaches are adapted into routine clinical practice. In addition, broad technical improvements in molecular detection assays and high throughput automation are pivotal for eventual clinical implementation. With the profile of the common and/or specific molecular changes in a particular tumor type rapidly evolving, emerging molecular detection approaches will become an important tool in the fight against cancer.
